References
S.D. Wiviott, I. Raz, M.P. Bonaca et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380(4), 347–357 (2019)
B. Neal, V. Perkovic, K.W. Mahaffey et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377(7), 644–657 (2017)
B. Zinman, C. Wanner, J.M. Lachin et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373(22), 2117–2128 (2015)
V. Perkovic, M.J. Jardine, B. Neal et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380(24), 2295–2306 (2019)
D. Fitchett, B. Zinman, C. Wanner et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the empa-reg outcome(r) trial. Eur. Heart J. 37(19), 1526–1534 (2016)
C. Wanner, S.E. Inzucchi, J.M. Lachin et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375(4), 323–334 (2016)
K. Radholm, G. Figtree, V. Perkovic et al. Canagliflozin and heart failure in type 2 diabetes mellitus. Circulation 138(5), 458–468 (2018)
V. Perkovic, D. de Zeeuw, K.W. Mahaffey et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the canvas program randomised clinical trials. Lancet Diabetes Endocrinol. 6(9), 691–704 (2018)
O. Mosenzon, S.D. Wiviott, A. Cahn et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the declare-timi 58 randomised trial. Lancet Diabetes Endocrinol. 7(8), 606–617 (2019)
K.W. Mahaffey, M.J. Jardine, S. Bompoint et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation 140(9), 739–750 (2019)
C.P. Cannon, V. Perkovic, R. Agarwal et al. Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline hba1c, including those with hba1c <7%: results from the credence trial. Circulation 141(5), 407–410 (2020)
J. McMurray, S.D. Solomon, S.E. Inzucchi et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381(21), 1995–2008 (2019)
T.A. Zelniker, S.D. Wiviott, I. Raz et al. Sglt2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393(10166), 31–39 (2019)
B.L. Neuen, T. Young, H. Heerspink et al. Sglt2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol, 7(11), 845–854 (2019)
C. Arnott, Q. Li, A. Kang et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J. Am. Heart Assoc. 9(3), e14908 (2020)
T. Toyama, B.L. Neuen, M. Jun et al. Effect of sglt2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis. Diabetes. Obes. Metab. 21(5), 1237–1250 (2019)
S.E. Inzucchi, D. Fitchett, D. Jurišić-Eržen et al. Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy? Diabetes Obes. Metab. 22(4), 631–639 (2020)
T. Ohkuma, L. Van Gaal, W. Shaw et al. Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the canvas program. Diabetes Obes. Metab. 22(4), 530–539 (2020)
J.B. Buse, D.J. Wexler, A. Tsapas et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the american diabetes association (ada) and the european association for the study of diabetes (easd). Diabetes Care 43(2), 487–493 (2020)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Qiu, M., Liu, SY., Gu, JS. et al. Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis. Endocrine 69, 688–691 (2020). https://doi.org/10.1007/s12020-020-02359-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-020-02359-5